News

Aytu BioPharma Acquires License to Develop DB102 for vEDS

Aytu BioPharma has acquired the option to license DB102 (enzastaurin), an investigational anti-tumor therapy with the potential to treat vascular Ehlers-Danlos syndrome, or vEDS. Denovo Biopharma, which holds worldwide rights to DB102 — originally developed as an oncology treatment — will continue to develop the oral therapy…

Rare Dental Lesions Found in Young Girl with EDS

A young girl diagnosed with Ehlers-Danlos syndrome (EDS) exhibited a rare case of so-called odontogenic keratocysts — benign cystic lesions characterized by aggressive growth — in her jaw, according to a case report. The report highlights the importance of an interdisciplinary approach for diagnosis and treatment of such complex…

EDS-related Gene Variants Found to Play Role in Eye Disorder

Genes involved in Ehlers-Danlos syndrome (EDS) appear to play a role in keratoconus (KC) — a thinning of the eye’s cornea. This finding, from a recent study, is the first to demonstrate shared genetic variations between the two disorders although their association has been suggested. The study, “…

Indigestion Common With Joint Hypermobility Syndrome for Reasons Unknown

Joint hypermobility syndrome, including hypermobile Ehlers–Danlos syndrome (hEDS), is present in a large proportion of people with functional dyspepsia — a common gastrointestinal disorder also known as indigestion without an underlying cause, a study showed. The presence of joint hypermobility, however, does not significantly prevent the digestive system from working…